425,000 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 425,000 shares of the biopharmaceutical company’s stock, valued at approximately $17,468,000. Ultragenyx Pharmaceutical comprises approximately 0.8% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 28th largest position. Frazier Life Sciences Management L.P. owned about 0.46% of Ultragenyx Pharmaceutical at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. TD Asset Management Inc boosted its position in Ultragenyx Pharmaceutical by 7.8% in the 4th quarter. TD Asset Management Inc now owns 221,360 shares of the biopharmaceutical company’s stock valued at $10,585,000 after buying an additional 16,000 shares during the last quarter. Treasurer of the State of North Carolina boosted its position in Ultragenyx Pharmaceutical by 17.3% in the 4th quarter. Treasurer of the State of North Carolina now owns 34,853 shares of the biopharmaceutical company’s stock valued at $1,667,000 after buying an additional 5,150 shares during the last quarter. Sands Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 59.8% in the 4th quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock valued at $196,923,000 after buying an additional 1,540,791 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Ultragenyx Pharmaceutical by 13.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 272,339 shares of the biopharmaceutical company’s stock valued at $13,023,000 after buying an additional 31,482 shares during the last quarter. Finally, NEOS Investment Management LLC bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $516,000. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 40,675 shares of company stock valued at $2,149,446. 5.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of recent research reports. The Goldman Sachs Group increased their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday. Wedbush increased their price target on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Finally, Barclays cut their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

Ultragenyx Pharmaceutical Trading Down 1.4 %

Shares of Ultragenyx Pharmaceutical stock opened at $54.43 on Friday. The company has a market capitalization of $5.02 billion, a PE ratio of -6.78 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $60.37. The stock’s fifty day simple moving average is $53.28 and its 200 day simple moving average is $46.69.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm’s revenue was up 35.7% compared to the same quarter last year. During the same quarter last year, the business posted ($2.25) EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.